Background An audit of thyroid function testing in the investigation of subclinical hypothyroidism in Scotland was performed.
Introduction
The aim of this audit was to examine the variety of comments biochemists add to laboratory reports. One of the more important functions of chemical pathologists and clinical scientists is in the post-analytical stage, with regard to interpretation and commenting on laboratory results and to suggest or perform additional tests as necessary. This function is currently being scrutinized more closely than before. 1, 2 It is not subject to any kind of quality control or peer review, nor is it a subject which is formally taught. It is recognized that there are signi¢cant di¡erences in the style and content of comments added to reports, and there is a growing awareness that some kind of external assessment may be desirable. In this study thyroid function test (TFT) results from patients with subclinical hypothyroidism were used to generate comments. This is a group where interpretative comments may aid appropriate investigation and treatment. 3 Recent review articles and consensus statements on the investigation and treatment of these patients were used to derive standards against which the comments were compared. 4^6
Methods
The audit questionnaire (see Appendix 1) was sent to the Heads of Department of each of the 25 biochemistry laboratories in Scotland. A ¢rst batch of questionnaires was sent to11laboratories, mainly in the west of Scotland, in February 1999, with a second batch of 14 questionnaires sent to the remaining laboratories throughout Scotland in June 2000.
The questionnaire consisted of two parts. The ¢rst considered the availability of thyroid function tests and how they were reported. The second consisted of six individual sets of thyroid function tests, accompanied by clinical details. It was requested that each person who routinely reported thyroid function tests would complete a copy of the second part of the questionnaire. Respondents were asked to comment on the results exactly as they would in the routine situation.
Results
Replies were obtained from 18 of the 25 Scottish laboratories. Table 1 shows the thyroid testing strategies used. Four laboratories did not add any interpretative comments to any of their thyroid reports. Fourteen laboratories did add comments: four of them added comments to every thyroid report, seven of them would not comment on reports destined for specialist clinics, and three would comment only if the results were abnormal. Only six of the laboratories had written guidelines on interpretative comments available.
Most laboratories had precoded comments available in their computer but ¢ve used only free text, sometimes handwritten. Six laboratories used a combination of precoded comments and free text. Twelve laboratories reported thyroid function tests in a cumulative format, where current results could be looked at in the context of previous results. Six laboratories did not provide cumulative reports. However, when laboratories were asked if they would look at previous results when commenting on results for a patient on thyroid replacement therapy, only 10 said they would always look at previous results, six said they would sometimes look at previous results, and two said they would seldom do so.
Thirteen laboratories had access to thyroid peroxidase antibody (TPO) estimation, either in-house or through another laboratory but ¢ve did not o¡er TPO estimation.
Standards for interpretive comments
The interpretive comments obtained in the audit must be compared with an accepted standard. No such evidence-based standards exist for commenting on results, and so standards had to be derived by the author. The current consensus is that patients who have a normal TT 4 or FT 4 with a raised thyroid-stimulating hormone (TSH), and who have raised titres of thyroid antibodies, particularly TPO antibodies, are at increased risk of developing overt thyroid disease, and treatment with thyroxine is recommended. 4^7,12 Therefore, it is suggested that TPO antibodies should be measured in all patients with normal TT 4 or FT 4 and a raised TSH to determine whether they fall into the higher risk category. TPO antibodies are more sensitive and speci¢c than antithyroglobulin antibodies (TG) in predicting thyroid failure. 4, 12 TSH can be raised for a variety of reasons, for example during non-thyroid illness, 8, 9 and so before measuring TPO antibodies it is advisable to repeat the TSH. In our experience TSH changes are relatively slow in patients with subclinical hypothyroidism, and repeating the TSH after a short time is not usually as informative as a repeat after some months. In most laboratories the exact period recommended for the repeat is tailored to the TSH level, but for the purpose of this audit, in the absence of evidence-based standards, it was decided that the standard for the repeat interval would be between 2 and 12 months. Before attempting to use published advice on TFT requesting to propose standards for laboratory report comments, it must be remembered that the clinical details given on a request form may be inadequate, non-existent or misleading. A vague, non-commital comment that helps the doctor to think about the patient may be better than a succinct, wrong comment which could lead to action detrimental to the patient. Bearing this in mind, the following scheme for commenting on results from patients with subclinical hypothyroidism was taken as a preliminary standard:
1. If a patient who is not on thyroid-related therapy has a TT 4 or an FT 4 within the reference range and a raised TSH, and there are no previous results available, the comment should include suggesting a repeat between 2 and 12 months later. 2. If a patient has a TT 4 or an FT 4 within the reference range and a TSH which has been raised for some months, the comment should include suggesting measurement of TPO antibodies. 3. If a patient has a TT 4 or FT 4 within the reference range, a TSH which is consistently raised and a raised titre of TPO antibodies, the comment should Total T 4 and TSH  Total T 3 and free T 4  3  Free T 4 and TSH  Total T 3  3  Free T 4 and TSH  Total T 3 and thyroid antibodies  2  Free T 4 and TSH  Total T 3 and thyroxine binding mention that the patient is at increased risk of overt thyroid disease and that thyroid function should be monitored.
These standards were applied to the comments received.
Four of the cases in the audit questionnaire were patients with subclinical hypothyroidism at various stages in the sequence of investigations outlined above. A variety of comments were received from the participants in this audit, and for reasons of clarity it was necessary to categorize them. For instance, the term`?Hypothyroid' includes received comments such as`Possible hypothyroidism',`Mildly hypothyroid', Developing hypothyroidism' and`Borderline hypothyroidism'. Likewise,`Subclinical hypothyroid' includes`Compensated euthyroid' and`Compensated hypothyroid', as well as`Subclinical hypothyroidism'. Case 1 (Fig. 1 ) was a patient with vague symptoms and a slightly raised TSH. According to the criteria given above, comments for this case should include a suggestion for repeat thyroid function tests between 2 and 12 months later.
Case 2 (Fig. 2 ) had a higher TSH of 10¢1mU/L. Using the derived standards a repeat sample after some months should be requested.
Case 3 (Fig. 3 ) showed the results obtained from a repeat specimen from a patient who previously had a slightly raised TSH. Using the proposed standards, TPO antibodies should be measured.
Case 4 ( Fig. 4 ) was a patient with a consistently slightly raised TSH and positive antibodies. According to advice given in the literature, 4^7 a trial of T 4 should be considered. However, when the clinical details may be incomplete or inaccurate, it may not be appropriate for the reporting biochemist to recommend a trial of T 4 without prior discussion with the requesting clinician. It is, however, appropriate and desirable to draw attention to the increased risk of thyroid disease and suggest long-term monitoring of thyroid function. Unfortunately, the serum TSH concentration of 4 ¢ 9 mU/L is above the reference range used by some laboratories, but within the reference range used in others. The ¢rst batch of audit questionnaires distributed did not quote reference ranges. It is di¤cult to draw conclusions from this case because a patient with raised TPO antibodies but a normal TSH does not have such an increased risk of developing thyroid disease, 5,10,11 and 33 of the 59 respondents regarded the TSH as being within the reference range. The lack of reference ranges had no e¡ect on the replies obtained for the other cases. The remaining cases looked at two possible causes of confusion with thyroid function test results. Case 5 (Fig. 5) was an acutely ill patient, a situation where testing of thyroid function is not advocated. 11 Reports on such cases should mention that non-thyroidal illness can cause misleading thyroid function test results, and should suggest a repeat after some months or when the patient is well. Case 6 ( Fig. 6 ) illustrated a problem of assay interference. This case showed one of the characteristic patterns that can be seen with assay interference: normal total and free T 4 results with a grossly elevated TSH. Ideally, a set of results like this should be checked within the laboratory ¢rst and, if con¢rmed, an aliquot of the sample should be assayed by di¡erent methods or further investigations performed until results are obtained which can be reported with con¢dence. Twenty-¢ve respondents suggested checking the results using di¡erent methods, although seven of them suggested checking only the TSH by a di¡erent method. Nine respondents suggested only checking the results, and two of them suggested checking only the TSH.
Discussion
The strategies used by the laboratories in Scotland for thyroid function testing were not dissimilar from those found by Barth et al. 13 in 1995, although no laboratory used either total or free T 4 alone as their front-line test.
The main aim of this audit was to study the comments biochemists (clinical scientists and chemical pathologists) used on thyroid function test reports. Biochemists have become accustomed to their analytical performance coming under scrutiny from external Quality Assessment (QA) schemes, but external evaluation of their comments is a new concept.
The major di¤culty when performing an audit such as this is the setting of standards. This may be seen by some as the ¢rst step to prescriptive commenting, but it was felt that recent guidelines 4^6 for the investigation and treatment of patients with subclinical hypothyroidism were a useful starting point for developing standards for comments. Standards are an integral part of any audit project^they may be subject to change as the audit loop is followed.
The results obtained showed that respondents had fairly wide di¡erences of opinion when commenting on these cases. In Case 2, for example, with a not uncommon set of results, some biochemists did not comment at all, but those who did so classi¢ed the patient variously as euthyroid, sick euthyroid, compensated hypothyroid or hypothyroid. Some suggested a repeat (between 1 and 6 months), and some did not. Some people asked for extra tests such as TPO antibodies; some did not. A similar variety of comments was seen in the other cases.
When the returns were compared against the proposed standards it was found that only four people returned comments consistent with those proposed for all cases. If Case 4 was not considered (reference ranges were omitted from the ¢rst batch of audit questionnaires) this number rose to ¢ve.
It is apparent that TPO antibody analysis is underutilized. Twenty-two of the 59 respondents did not mention thyroid antibody estimation. Most people were aware of the problems associated with measuring thyroid function tests in the sick patient, and most people recognized the picture given by assay interference.
One aim of clinical audit is to reduce variation in clinical practice. It is intended to perform a follow-up audit to reassess the consistency of reporting in Scottish laboratories.
Conclusion
There is considerable variation in the practice of thyroid function testing by laboratories, and considerable diversity in the interpretation of subclinical hypothyroid results by clinical scientists and chemical pathologists. This applies to the terminology used to describe the condition, the tests used to investigate it, the suggested time before repeating tests, the second-line tests^particularly TPO antibodies^and the comments and advice annotated to the report. There is clearly a need to establish evidence-based or consensus guidelines to promote consistency both within and between laboratories investigating subclinical hypothyroidism and interpreting the results. The importance of TPO antibody estimation in this condition needs to be emphasized. It is also apparent that a number of comments made by clinical scientists and chemical pathologists on thyroid function test results are not in line with current advice concerning the diagnosis and treatment of subclinical hypothyroidism. This highlights the need for an external quality assessment scheme for report commenting. 
Part 2
Please give a copy of this part of the questionnaire to each person who comments on thyroid function tests We would be grateful if each person would answer this part individually. The purpose of this part of the questionnaire is to investigate the consistency of commenting on thyroid function test reports across Scotland. Participants are asked to comment on the following sets of thyroid results. Please comment exactly as you would if these were routine results in your laboratory, i.e. it may be you spend less than a minute on each. Please indicate if you would carry out further tests, or suggest further tests. This is not an exam and there are no right answers^nor are you expected to come up with a full diagnosis from one set of results: vague comments are acceptable. If you would normally confer with a colleague please feel free to do so.
Please write your comments alongside the results.
( 
